FibroGen, Inc. Securities Litigation Settlement
Last verified July 16, 2026Source: jndHow ClaimWatch verifies cases
Closed to new claims. Browse open settlements →
Where this case stands
Payments distributed June 13, 2025
The court approved the settlement and the administrator has reported sending payments to class members who filed valid claims.
Before Judge Edward M. Chen, U.S. District Court (No. 3:21-cv-02623-EMC).
- April 12, 2021Case filed
- January 7, 2025Preliminary approval
The court allowed notice of the proposed settlement to go out to the class.
- June 13, 2025Payments distributed
- December 9, 2025Final approval granted
- December 9, 2025Case closed by the court
What happened
FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.
Do you qualify?
Anyone who purchased or acquired FibroGen, Inc. securities, including options, between December 20, 2018 and July 15, 2021, inclusive. Excluded are defendants, company officers and directors during the class period, their immediate family members, and entities they owned or controlled.
How to file
Contact the Claims Administrator at (877) 595-0137 or Info@FibroGenSecuritiesLitigation.com. The settlement is in distribution phase as of February 12, 2025, with ongoing rolling distributions to approved claimants. No new claims appear to be accepted as the distribution has already commenced.
Common questions
- How much does the FibroGen, Inc. Securities Litigation Settlement pay?
- The settlement fund is $28.5M.Why settlement checks are smaller than the headline number →
- What is the status of the FibroGen, Inc. Securities Litigation Settlement?
- Payments distributed June 13, 2025. The court approved the settlement and the administrator has reported sending payments to class members who filed valid claims.
- Is the FibroGen, Inc. Securities Litigation Settlement notice real, or a scam?
- JND Legal Administration is the court-appointed administrator. Claims are filed only at fibrogensecuritieslitigation.com. Filing is always free, and no administrator asks for payment or a full Social Security number by email or text.How to tell a real settlement notice from a scam →
- Who are the attorneys in the FibroGen, Inc. Securities Litigation Settlement?
- For the plaintiffs: Peretz Bronstein (Bronstein, Gewirtz & Grossman, LLC (NY)); Jeremy A. Lieberman (Pomerantz LLP); J Alexander Hood , II (Pomerantz LLP); Jennifer Pafiti (Pomerantz LLP). For FibroGen, Inc., Enrique Conterno, James A. Schoeneck, Mark Eisner, Pat Cotroneo, and K. Peony Yu: Brett De Jarnette (Cooley LLP); Tijana Brien (Cooley LLP); Eric Wei (Wei Group LLP); Caitlin B Munley (Cooley LLP - Library). From the public court docket.
Who's involved
Plaintiffs
- Cesare Grazioli
- Peifa Xu
Defendants
- Pat Cotroneo
- Mark Eisner
- K. Peony Yu
- James Schoeneck
- Enrique Conterno
- FibroGen, Inc.
Counsel for plaintiffs
- Peretz BronsteinBronstein, Gewirtz & Grossman, LLC (NY)Represents Cesare Grazioliperetz@bgandg.com · (212) 697-6484
- Jeremy A. LiebermanPomerantz LLPRepresents Cesare Grazioli20 tracked cases · $637.4M in disclosed settlementsjalieberman@pomlaw.com · (212) 661-1100
- J Alexander Hood , IIPomerantz LLPRepresents Cesare Grazioli10 tracked cases · $360.8M in disclosed settlementsahood@pomlaw.com · (212) 661-1100
- Jennifer PafitiPomerantz LLPRepresents Cesare Grazioli15 tracked cases · $304.8M in disclosed settlementsjpafiti@pomlaw.com · (310) 405-7190
- Jeffrey John MilesCarlton FieldsRepresents Peifa Xu2 tracked cases · $28.5M in disclosed settlementsjeff.miles@carltonfields.com · (310) 843-6318
- Nicole Catherine LavalleeBerman TabaccoRepresents Peifa Xu2 tracked cases · $28.5M in disclosed settlementsnlavallee@bermantabacco.com · (415) 433-3200
Counsel for defendants
- Brett De JarnetteCooley LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneo3 tracked cases · $60.5M in disclosed settlements defendedbdejarnette@cooley.com · (650) 849-7005
- Tijana BrienCooley LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneotbrien@cooley.com · (650) 843-5000
- Eric WeiWei Group LLPRepresents K. Peony Yuewei@weillp.com · (212) 248-0808
- Caitlin B MunleyCooley LLP - LibraryRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneocmunley@cooley.com · (202) 776-2557
- Amie Lea SimmonsCooley LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneo3 tracked cases · $60.5M in disclosed settlements defendedasimmons@cooley.com · (650) 843-5000
- Alexandra EberCooley LLP - LibraryRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneoaeber@cooley.com · (202) 776-2983
- Zaneta J KimGibson Dunn & Crutcher LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneozkim@gibsondunn.com · (650) 849-5388
- Patrick Edward GibbsCooley LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneo2 tracked cases · $60.5M in disclosed settlements defendedpgibbs@cooley.com · (650) 843-5000
- Jessica ValenzuelaGibson Dunn & Crutcher LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneojvalenzuela@gibsondunn.com · (650) 849-5300
- Alexander J. KasnerCooley LLP - LibraryRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneo2 tracked cases · $28.5M in disclosed settlements defendedakasner@cooley.com · (202) 776-2266
- Lee BrandPillsbury Winthrop Shaw Pittman LLPRepresents K. Peony Yu3 tracked cases · $28.5M in disclosed settlements defendedlee.brand@pillsburylaw.com · (415) 983-1000
- Bruce A. EricsonPillsbury Winthrop Shaw Pittman LLPRepresents K. Peony Yu2 tracked cases · $28.5M in disclosed settlements defendedbruce.ericson@pillsburylaw.com · (415) 983-1000
- John C. DwyerCooley LLPRepresents FibroGen, Inc., Enrique Conterno, James Schoeneck, Mark Eisner, Pat Cotroneo2 tracked cases · $76.5M in disclosed settlements defendeddwyerjc@cooley.com · (650) 843-5000
Other cases these firms appear in
- Celsius Network Fraud Class Action · Pomerantz LLP
- Apple Consumer Fraud Class Action · Pomerantz LLP
- Saratoga Hospital ERISA Class Action · Pomerantz LLP
- Luna Innovations Incorporated Securities Litigation Settlement · Pomerantz LLP
- Davis v. Drapify Home Class Action · Carlton Fields, P.A.
From the public court docket, contact details as filed; not an endorsement.
In the news
- FibroGen announces rebrand as Kyntra BioThefly.com · January 7, 2026
- FibroGen granted orphan drug designation for roxadustat in MDSThefly.com · December 15, 2025
- FibroGen reports Q3 EPS ($3.25), consensus ($4.01)Thefly.com · November 10, 2025
- FibroGen initiates Phase 2 trial of FG-3246Thefly.com · September 24, 2025
Headlines via NewsAPI.
Guides:Why is my settlement check so small?How long a settlement takes to pay outIs this settlement notice real, or a scam?
Summarised from public settlement documents; confirm terms on the official settlement website. ClaimWatch is not a law firm, and filing a claim is free.